EPO Receptor Gain-of-function Causes Hereditary Polycythemia, Alters CD34 Cell Differentiation and Increases Circulating Endothelial Precursors
Overview
Authors
Affiliations
Background: Gain-of-function of erythropoietin receptor (EPOR) mutations represent the major cause of primary hereditary polycythemia. EPOR is also found in non-erythroid tissues, although its physiological role is still undefined.
Methodology/principal Findings: We describe a family with polycythemia due to a heterozygous mutation of the EPOR gene that causes a G-->T change at nucleotide 1251 of exon 8. The novel EPOR G1251T mutation results in the replacement of a glutamate residue by a stop codon at amino acid 393. Differently from polycythemia vera, EPOR G1251T CD34(+) cells proliferate and differentiate towards the erythroid phenotype in the presence of minimal amounts of EPO. Moreover, the affected individuals show a 20-fold increase of circulating endothelial precursors. The analysis of erythroid precursor membranes demonstrates a heretofore undescribed accumulation of the truncated EPOR, probably due to the absence of residues involved in the EPO-dependent receptor internalization and degradation. Mutated receptor expression in EPOR-negative cells results in EPOR and Stat5 phosphorylation. Moreover, patient erythroid precursors present an increased activation of EPOR and its effectors, including Stat5 and Erk1/2 pathway.
Conclusions/significance: Our data provide an unanticipated mechanism for autosomal dominant inherited polycythemia due to a heterozygous EPOR mutation and suggest a regulatory role of EPO/EPOR pathway in human circulating endothelial precursors homeostasis.
Erythropoietin: A Personal Alice in Wonderland Trip in the Shadow of the Giants.
Migliaccio A Biomolecules. 2024; 14(4).
PMID: 38672425 PMC: 11047939. DOI: 10.3390/biom14040408.
Lo Riso L, Vargas-Parra G, Navarro G, Arenillas L, Fernandez-Ibarrondo L, Robredo B Genes (Basel). 2022; 13(10).
PMID: 36292571 PMC: 9601602. DOI: 10.3390/genes13101686.
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
Gangat N, Szuber N, Pardanani A, Tefferi A Leukemia. 2021; 35(8):2166-2181.
PMID: 34021251 PMC: 8324477. DOI: 10.1038/s41375-021-01290-6.
PLoS One. 2020; 15(3):e0230279.
PMID: 32130275 PMC: 7055919. DOI: 10.1371/journal.pone.0230279.
Oskarsson G, Kristjansson R, Lee A, Sveinbjornsson G, Magnusson M, Ivarsdottir E Commun Biol. 2018; 1:49.
PMID: 30271932 PMC: 6123817. DOI: 10.1038/s42003-018-0053-3.